| abstract |
The disclosure relates generally to activatable antibodies that bind to CD 147 and methods of making and using these activatable antibodies in a variety of therapeutic, prophylactic, and diagnostic contexts. In some embodiments, the CD 147 activatable antibodies bind human and cynomolgus monkey CD 147. |